Development and clinical application of a methylated ctDNA assay in the preoperative risk classification of resectable colon cancer
Authors:
- Louise RaunkildeLRLouise Raunkilde
- M JørgensenMJM Jørgensen
- Lars Henrik JensenLJLars Henrik Jensen
Preprint
Abstract
Background: Pathological lymph node involvement (pN+) is an indicator of poor prognosis in localized colon cancer. Currently, the preoperative risk classification fails to accurately identify pN+, which could be instrumental in the selection of patients for neoadjuvant chemotherapy (NAC). This study aimed to develop an assay for preoperative methylated circulating tumor DNA (meth-ctDNA) as a predictive marker of pN+ and as a biomarker for initiating NAC in patients with localized colon cancer. Materials and methods: 203 patients operated for colon cancer stage I-III at Vejle Hospital were randomly assigned (1:1) to a discovery and a validation cohort. A multiplex assay of a tumor-specific (NPY) and two organ-specific (GAL3ST3, KANK1) meth-ctDNAs was designed and methylation analysis was performed using droplet digital PCR. The ability of preoperative meth-ctDNA to predict pN+ was assessed using receiver operating characteristics (ROC) analysis. Results: ROC analyses of meth-ctDNA (negative/positive) to predict pN+ had an area under the curve of 52% and 57% in the discovery and validation cohort, respectively. Survival analysis in the validation cohort confirmed a higher rate of 48 months disease-free survival in meth-ctDNA negative compared to positive patients (HR=2.31, 95% CI 1.01-5.2). The difference also applied to 4-year overall survival (HR=3.62, 95% CI 1.15-11.4). In a multivariate analysis, meth-ctDNA remained the strongest prognostic factor of DFS (HR 2.46, 95% CI 1.03-5.88) and OS (HR 4.54, 95% CI 1.32-15.6) in relation to clinical T- or N-category, gender and age. Conclusion: The preoperative meth-ctDNA multiplex assay did not predict pN+. The findings suggest meth-ctDNA as a more powerful marker than N-category in identifying high-risk patients who would potentially benefit from NAC.Keywords
This publication has 37 references indexed in Scilit:
- The diagnostic accuracy of local staging in colon cancer based on computed tomography (CT): evaluating the role of extramural venous invasion and tumour depositsAbdominal Radiology, 2023
- A universal cell‐free DNA approach for response prediction to preoperative chemoradiation in rectal cancerInternational Journal of Cancer, 2022
- LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 studyAnnals of Oncology, 2022
- Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utilityCancer, 2022
- Age‐stratified reference intervals unlock the clinical potential of circulating cell‐free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancerInternational Journal of Cancer, 2020
- Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studiesInternational Journal of Cancer, 2020
- Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancerAnnals of Oncology, 2020
- Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer PatientsClinical Colorectal Cancer, 2018
- Potential impact of invasive surgical procedures on primary tumor growth and metastasisClinical & Experimental Metastasis, 2018
- Controls to validate plasma samples for cell free DNA quantificationClinica Chimica Acta, 2015